NCT04321902

Brief Summary

In this study, the investigators compared the surgical outcomes according to the type of antibiotics before surgery in patients who did not have evidence of systemic infection during acute cholecystitis. The primary purpose of the study was to determine the type of preoperative antibiotics in patients who were scheduled for cholecystectomy, because of the mild (grade I) or moderate (grade 2) acute inflammatory gallbladder disease without gallbladder perforation. The investigators compared the incidence of postoperative complications according to the types of preoperative antibiotics(the first-generation vs second-generation cephalosporin). The secondary purpose of the study was to confirm the clinical efficacy of first-generation cephalosporins following the use of empirical antibiotics. And the investigators compare with postoperative pain, postoperative hospital stay, re-hospitalization, and need for additional treatment. In addition, the investigators compare the postoperative complications, such as atelectasis and postoperative ileus.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
350

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Apr 2020

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 16, 2019

Completed
8 months until next milestone

First Posted

Study publicly available on registry

March 25, 2020

Completed
8 days until next milestone

Study Start

First participant enrolled

April 2, 2020

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2020

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2021

Completed
Last Updated

March 25, 2020

Status Verified

March 1, 2020

Enrollment Period

9 months

First QC Date

July 16, 2019

Last Update Submit

March 23, 2020

Conditions

Keywords

empirical antibioticspostoperative complication

Outcome Measures

Primary Outcomes (1)

  • Number of Participants with Infectious Postoperative Complications

    Incidence of infectious postoperative complications in patients who underwent a laparoscopic cholecystectomy due to grade I Tokyo guidelines for acute cholecystitis or grade II Tokyo guidelines for acute cholecystitis except the evidence of gallbladder perforation, with the first-generation cephalosporin and the second-generation cephalosporin.

    30 days

Secondary Outcomes (1)

  • Duration of hospitalization

    Participants will be followed for the duration of hospital stay, an expected average of 2 days

Study Arms (2)

The experimental group in acute cholecystitis

EXPERIMENTAL

inclusion criteria 1. among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II) 2. cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging 3. Gallbladder with surrounding organs due to gallbladder inflammation 4. Patients over 19 years of age First-generation cephalosporin (Cefazolin inj., 1g, Cefazolin sodium, Chong-geun-dang pharm.co.) was used as before and during surgery.

Procedure: Laparoscopic cholecystectomy

The controled group in acute cholecystitis

EXPERIMENTAL

1. among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II) 2. cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging 3. Gallbladder with surrounding organs due to gallbladder inflammation 4. Patients over 19 years of age Sencond-generation cephalosporin (Shincef inj., 750mg, Cefuroxime sodium, Shin-poong pharm.co.) was used as before and during surgery.

Procedure: Laparoscopic cholecystectomy

Interventions

Method of operation 1. Surgery was started under general anesthesia 2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and 5 mm trocar was placed on the right upper abdomen. 3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity. 4. Dissection started from Calot's triangle and the operation was performed by retrograde cholecystectomy. 5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus. 6. The trocar was removed and the skin was sutured On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)

Also known as: hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed
The controled group in acute cholecystitisThe experimental group in acute cholecystitis

Eligibility Criteria

Age19 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • among patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation(grade II)
  • cholecystitis with a thickness of 4 mm or more on gallbladder in preoperative imaging
  • Gallbladder with surrounding organs due to gallbladder inflammation
  • Patients over 19 years of age, under 70 years of age

You may not qualify if:

  • patients with elective gallbladder surgery (chronic cholecystitis)
  • gallbladder disease not inflammatory disease (GB cancer, GB polyp)
  • pregnant women, patients under 18 years of age, over 70 years of age
  • patients with simultaneous surgery due to other organ diseases
  • immunosuppressed patients; liver transplant patients, kidney transplant patients, acquired immunodeficiency syndrome patients
  • patients with hemorrhagic tendency, or with hematologic diseases
  • Patients who underwent percutaneous cholecystectomy (PTGBD)
  • Patients with acute cholecystitis who had gallbladder perforation, grade II or III by Tokyo guidelines

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of HBP Surgery, Seoul St. Mary's hospital

Seoul, Seocho-gu, Banopo-dong, 137-701, South Korea

Location

MeSH Terms

Conditions

Cholecystitis, AcutePostoperative Complications

Interventions

Cholecystectomy, LaparoscopicHematologic TestsBlood Chemical AnalysisUrinationBlood Coagulation

Condition Hierarchy (Ancestors)

CholecystitisGallbladder DiseasesBiliary Tract DiseasesDigestive System DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

CholecystectomyBiliary Tract Surgical ProceduresDigestive System Surgical ProceduresSurgical Procedures, OperativeLaparoscopyEndoscopyMinimally Invasive Surgical ProceduresClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisInvestigative TechniquesClinical Chemistry TestsUrinary Tract Physiological PhenomenaReproductive and Urinary Physiological PhenomenaHemostasisBlood Physiological PhenomenaCirculatory and Respiratory Physiological Phenomena

Study Officials

  • Sung eun Park, MD

    The Catholic University of Korea

    STUDY DIRECTOR

Central Study Contacts

Tae ho Hong, MD. PhD

CONTACT

Eun young Kim, MD. PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

July 16, 2019

First Posted

March 25, 2020

Study Start

April 2, 2020

Primary Completion

December 30, 2020

Study Completion

December 30, 2021

Last Updated

March 25, 2020

Record last verified: 2020-03

Data Sharing

IPD Sharing
Will not share

Locations